ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Hanmi Science Co., Ltd.

  • 49,000.00 KRW
  • +450.00
  • +0.93%
  • South Korea
    Jul 15, 2019
  • Ticker
  • Prev. close
  • Market cap (KRW)
  • Market cap (USD)
  • Shares

Company Background

Hanmi Science is a holding company with two core subsidiaries: Hanmi Pharmaceutical, which develops and produces medicines, and Online Pharm, a drug wholesaler. In recent years, the South Korean group has been actively developing new drugs. It has also accelerated overseas expansion, including by setting up a unit in Beijing.

The company's market capitalization puts it in the top tier of South Korean drug companies, alongside Celltrion.

The group was established in 1973 as Hanmi Pharmaceutical. It strengthened its presence in the drug development game in the 2000s. About 20% of sales are reinvested in research and development.

Hanmi has been focusing on clinical trials for diabetes treatments. It expects the diabetes drug market to grow at an average annual pace of over 6% from 2014 to 2023, nearly doubling in size to $42 billion.

The company's operations include original design manufacturing services for major international drugmakers, including France's Sanofi. For this, Hanmi uses a plant in Hwaseong, Gyeonggi Province. It also runs a facility for antibiotics and biotechnology in Pyeongtaek, in the same province.

Hanmi Fine Chemical, another group company, produces active pharmaceutical ingredients for major drugmakers.

In July 2015, Hanmi announced a partnership with German drugmaker Boehringer Ingelheim. The duo aims to develop a pharmaceutical candidate, HM61713, into a new molecularly targeted drug for lung cancer treatment. Hanmi is to put the drug through clinical trials in South Korea, China and Hong Kong, as well as handle sales licensing, production and commercialization in those markets.

Under the deal, Hanmi will start by using $50 million in contract money to conduct clinical development. The South Korean company stands to receive a total of $730 million, based on progress with licensing and other tasks.

Business Summary

Hanmi Science Co., Ltd. is a holding company that engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong, South Korea.

Financial Highlights

Dec 2018 KRWUSD
Gross Profit24,022.63M21.82M
Operating income10,996.88M9.99M
Income before tax24,434.58M22.20M
Net income23,370.15M21.23M
Diluted EPS376.350.34
Dividends Per Share196.070.17
Total Assets922,160.62M826.45M
Total liabilities263,716.07M236.34M
Total equity658,444.10M590.10M
Operating cash flow2,701.37M2.45M
Currency in KRWCurrency in USD

Historical Data

 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 532,886.46M 776,628.55M 665,284.66M 652,324.36M 707,995.35M
Gross Profit 18,462.70M 157,090.07M 27,678.49M 28,307.25M 24,022.63M
Operating income 9,293.29M 147,069.05M 15,067.31M 12,704.64M 10,996.88M
Income before tax 10,490.42M 164,384.79M 5,329.86M 33,398.11M 24,434.58M
Net income 21,312.16M 178,520.88M 7,937.68M 30,068.97M 23,370.15M
EBITDA 10,660.00M 149,100.63M 18,272.20M 17,388.56M 15,602.45M
Diluted EPS 339.94 2,845.77 125.76 478.43 376.35
Dividends Per Share 0 440.33 411.52 192.23 196.07
Total Assets 742,795.23M 932,024.38M 969,248.66M 938,783.18M 922,160.62M
Total liabilities 325,083.42M 347,774.73M 321,684.81M 273,630.93M 263,716.07M
Total equity 416,055.37M 583,680.58M 645,286.62M 665,154.16M 658,444.10M
Operating cash flow 5,245.49M 46,927.26M 85,043.35M -33,466.88M 2,701.37M
 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 506.22M 686.18M 573.42M 577.01M 643.32M
Gross Profit 17.53M 138.79M 23.85M 25.03M 21.82M
Operating income 8.82M 129.94M 12.98M 11.23M 9.99M
Income before tax 9.96M 145.24M 4.59M 29.54M 22.20M
Net income 20.24M 157.73M 6.84M 26.59M 21.23M
EBITDA 10.12M 131.73M 15.74M 15.38M 14.17M
Diluted EPS 0.32 2.51 0.10 0.42 0.34
Dividends Per Share 0 0.38 0.35 0.17 0.17
Total Assets 675.79M 794.86M 802.49M 876.91M 826.45M
Total liabilities 295.75M 296.59M 266.33M 255.59M 236.34M
Total equity 378.52M 497.78M 534.26M 621.32M 590.10M
Operating cash flow 4.98M 41.46M 73.30M -29.60M 2.45M

Valuation Measures

Dec 2018
Operating margin1.55%
Profit margin3.30%

Key executives

  • Co-President, Co-CEO & Director: Sae-Chang Kwon
  • Co-President, Co-CEO & Director: Jong-Soo Woo
  • Co-President & Director: Chong-Yoon Lim
  • Chairman-Executive Board: Sung-Gi Lim
  • Senior Managing Director: Jong-Ho Lim


  • LIM SUNG-GI (34.2%)
  • SHIN DONG-GUK (12.1%)
  • Hanmi Healthcare Co., Ltd. (6.4%)
  • LIM JONG YOON (3.6%)
  • LIM JU-HYUN (3.5%)
  • LIM JONG-HOON (3.1%)
  • LIM JIN-HEE (2.2%)
  • Hanmi Science Co., Ltd. (2.0%)

Contact Details

  • Website:
  • Address: 214 Muha-ro, Paltan-myeon, Hwaseong, 18536, South Korea
  • Phone: +82.31.410.9114

Related Companies

  • Online Pharm. Co., Ltd.


    Last Updated on 15 Jul, 2019

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Get Unlimited access

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends June 30th

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to the Nikkei Asian Review has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media